221 related articles for article (PubMed ID: 24023300)
21. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
22. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
23. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
24. Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients.
Burke MT; Morais C; Oliver KA; Lambie DL; Gobe GC; Carroll RP; Staatz CE; Sinnya S; Soyer HP; Winterford C; Haass NK; Campbell SB; Isbel NM
Am J Clin Pathol; 2015 Apr; 143(4):514-26. PubMed ID: 25780003
[TBL] [Abstract][Full Text] [Related]
25. The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.
Schaper-Gerhardt K; Walter A; Schmitz-Rode C; Satzger I; Gutzmer R
J Dermatol Sci; 2018 Nov; 92(2):172-180. PubMed ID: 30220530
[TBL] [Abstract][Full Text] [Related]
26. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
27. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of ezrin in cutaneous basal and squamous cell carcinomas.
Abdou AG; Maraee AH; El-Sayed EM; Elnaidany NF
Ann Diagn Pathol; 2011 Dec; 15(6):394-401. PubMed ID: 21849257
[TBL] [Abstract][Full Text] [Related]
29. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
[TBL] [Abstract][Full Text] [Related]
30. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
31. MTOR promotes basal cell carcinoma growth through atypical PKC.
Chow RY; Levee TM; Kaur G; Cedeno DP; Doan LT; Atwood SX
Exp Dermatol; 2021 Mar; 30(3):358-366. PubMed ID: 33617094
[TBL] [Abstract][Full Text] [Related]
32. Proteinase-activated receptor-2 expression in basal and squamous cell carcinomas compared with normal skin.
Dastgheib L; Monabati A; Mohammadian A; Sari-Aslani F; Marzban S; Namazi MR
J Cutan Pathol; 2009 Mar; 36(3):314-7. PubMed ID: 19032384
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment.
Kim C; Cheng J; Colegio OR
Semin Oncol; 2016 Jun; 43(3):390-4. PubMed ID: 27178693
[TBL] [Abstract][Full Text] [Related]
34. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
35. Differential immunohistochemical expression of matrix metalloproteinase-10 (MMP-10) in non-melanoma skin cancers of the head and neck.
Kadeh H; Saravani S; Heydari F; Shahraki S
Pathol Res Pract; 2016 Oct; 212(10):867-871. PubMed ID: 27567711
[TBL] [Abstract][Full Text] [Related]
36. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
Rival-Tringali AL; Euvrard S; Decullier E; Claudy A; Faure M; Kanitakis J
Anticancer Res; 2009 Jun; 29(6):1927-32. PubMed ID: 19528449
[TBL] [Abstract][Full Text] [Related]
37. Transplantation: time to rethink immunosuppression by mTOR inhibitors?
Säemann MD; Remuzzi G
Nat Rev Nephrol; 2009 Nov; 5(11):611-2. PubMed ID: 19855420
[TBL] [Abstract][Full Text] [Related]
38. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
39. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
[TBL] [Abstract][Full Text] [Related]
40. Immunolocalization of glioma-associated oncogene homolog 1 in non melanoma skin cancer.
Bakry OA; Samaka RM; Shoeib MA; Megahed DM
Ultrastruct Pathol; 2015 Apr; 39(2):135-46. PubMed ID: 25350271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
